Table 1.
Clinical Factors in MS patients with positive and negative spike antibody response.
| Clinical factors, n (%) | Positive SARS-CoV-2 spike protein antibody (n=29) | Negative SARS-CoV-2 spike protein antibody (n=21) | Statistical test | P-value |
|---|---|---|---|---|
| Female | 24 (83%) | 15 (71%) | X2 = 0.9112 | 0.34 |
| White | 23 (79%) | 16 (83%) | X2 = 0.0691 | 0.79 |
| Relapsing remitting course (RRMS) | 18 (62%) | 7 (33%) | X2 = 4.02 | 0.04 |
| Primary progressive course (PPMS) | 4 (14%) | 2 (10%) | X2 = 0.2102 | 0.65 |
| mRNA vaccine (Pfizer/BioNTech, Moderna) | 27 (93%) | 19 (90%) | Fisher's Exact | 1.00 |
| Viral vector vaccine (Janssen) | 2 (7%) | 2 (10%) | Fisher's Exact | 1.00 |
| Pfizer vaccine* | 15/24 (63%) | 12/17 (71%) | X2 = 0.29 | 0.59 |
| Moderna vaccine* | 9/24 (35%) | 5/17 (29%) | X2 = 0.55 | 0.59 |
| Lymphopenia (<1 × 109/L) | 6 (21%) | 5 (24%) | X2 = 0.069 | 0.79 |
| B-cell therapy | 9 (31%) | 18 (86%) | X2 = 14.66 | 0.001 |
| Fumarates | 9 (31%) | 1 (4.8%) | Fisher's Exact | 0.0313 |
| S1P modulators | 3 (10%) | 1 (4.8%) | Fisher's Exact | 0.63 |
| MMF/cladribine | 3 (10%) | 1 (4.8%) | Fisher's Exact | 0.63 |
| Average age | 50.52 ± 12.30 | 55.14 ± 11.94 | t= 1.33 | 0.19 |
| Average absolute lymphocyte count | 1.19 ± 0.68 | 1.23 ± 0.69 | t= 2.16 | 0.83 |
*n=46, comparing Moderna to Pfizer vaccine. 4 patients received Janssen vaccine and were not included in the analysis.